What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.

ABSTRACT:

Background

Decisions about adjuvant therapy involve trade-offs between possible benefits and harms.

Objective

We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for apparently localised renal cell carcinoma (RCC).

Methods

A subset of clinical investigators in the SORCE trial completed a validated questionnaire that elicited the minimum survival benefits they judged sufficient to warrant one year of adjuvant sorafenib in scenarios with hypothetical baseline survival times of 5 years and 15 years, and baseline survival rates at 5 years of 65% and 85%.

Results

The 100 participating SORCE investigators had a median age of 42 years, and 7

SUBMITTER: Lawrence NJ 

PROVIDER: S-EPMC6364092 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature